title: [Ocular myasthenia: clinical course and strategies for treatment].
abstract: BACKGROUND
  Ocular myasthenia gravis is a localized form of myasthenia in which only the extra-ocular muscles are clinically affected, namely the levator palpebrae superioris and orbicularis oculi. Two years after onset of the ocular condition, it became generalized in 44-53% of the patients.
  
  
  OBJECTIVE
  1. To describe the clinical features, diagnostic characteristics and clinical course of seven patients who fulfilled the criteria for diagnosis of ocular myasthenia and in whom the condition did not become generalized: 2. Review recent papers on this. Material and methods. We studied seven patients (two men and two women) diagnosed as having ocular myasthenia gravis, and followed them up for at least three years.
  
  
  RESULTS
  The average age was 56.5. The clinical findings were of ptosis of the eyelids and diplopia. All seven patients were treated with pyridostigmine. In six cases prednisone was also given and in one patient thymectomy was done. There was a satisfactory result in all cases.
  
  
  CONCLUSIONS
  The basic treatment of ocular myasthenia is with anticholinesterases and corticosteroids. Occasionally other immunosuppressives may be required. Prednisone seems to reduce the number of patients who go on to develop the generalized form.
authors.affiliation: Servicio de Neurología, Hospital Miguel Servet, Zaragoza, España.
authors.forename: M E
authors.initials: ME
authors.lastname: Marzo
authors.forename: I
authors.initials: I
authors.lastname: Pérez López-Fraile
authors.forename: J L
authors.initials: JL
authors.lastname: Capablo
authors.forename: J R
authors.initials: JR
authors.lastname: Ara
authors.forename: M
authors.initials: M
authors.lastname: Usón
mesh_terms: D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001763:Blepharoptosis / Q000150:complications; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004172:Diplopia / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy*; D015835:Ocular Motility Disorders / Q000209:etiology* / Q000628:therapy*; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D011729:Pyridostigmine Bromide / Q000627:therapeutic use*; D013934:Thymectomy
chemical_list: D000893:Anti-Inflammatory Agents; D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide; D011241:Prednisone
vernacular_title: Miastenia ocular: evolución clínica y estrategia terapéutica.